Atopic Dermatitis

An expert dermatologist provides insight on unmet needs in clinical trial endpoint measurements that would improve the management of atopic dermatitis.

Dr Andrew Blauvelt discusses the relevance of dupilumab treatment response as seen in the LIBERTY AD OLE and LIBERTY AD CHRONOS studies and shares his approaches to improving atopic dermatitis management.

Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, talks about how education of patients is so important, the upcoming parts of the AAD guidelines to look forward to, and more.

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research expands on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is held from April 9 to 11 in Baltimore, Maryland.

Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, discusses the American Academy of Dermatology's approach to atopic dermatitis management.

What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.

Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, California, discusses the importance of recognizing children with more severe atopic disease and a team approach to treatment.

Brett King, MD, of Yale School of Medicine, discusses the future of atopic dermatitis treatment.

A RAD conference abstract presentation highlights the demographic, prevalence, and comorbidity data for adults with atopic dermatitis.

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research, explores the hidden burdens of itch that many pediatric patients and parents have to deal with on a daily basis. She expanded on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference was held from April 9 to 11 in Baltimore, Maryland

In her talk at the Revolutionizing Atopic Dermatitis Conference, Madison Cook, BS, gives tips on how to increase accountability, common barriers to overcome with patients, and more.

What do topical PDE4 inhibitors bring to the treatment toolbox? Which patients are likely to get the most use out of them? Robert Sidbury, MD, MPH, answers these questions and more in this video interview.

An abstract presented at the Revolutionizing Atopic Dermatitis conference discussed the impact of treatment with dupilumab on quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.

Experts take a closer look at when to watch, and what to watch for in patients on JAK inhibitors.

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research dives into the importance of the results from their recently released study.

Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, expands on his AD overview from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is being held from April 9 to 11 in Baltimore, Maryland.

The Revolutionizing Atopic Dermatitis conference begins with presentations focused on new treatments, data, and more in atopic dermatitis.

Andrew Blauvelt, MD, MBA, reviews clinical implications from the phase 3 LIBERTY AD CHRONOS study examining the efficacy of dupilumab plus topical corticosteroids in adult patients with moderate to severe atopic dermatitis.

An expert dermatologist provides key takeaways and the real-world significance of dupilumab use for the treatment of atopic dermatitis.

LEO Pharma presented long-term data from an interim analysis of its ECZTEND 5-year extension trial, showing no new safety signals.

A poster from the 2022 American Academy of Dermatology Annual Meeting gathered the real-world data around patients using dupilumab to treat atopic dermatitis.

Dr Andrew Blauvelt reviews key highlights and clinical implications from the LIBERTY AD OLE study assessing the effect of long-term dupilumab treatment on efficacy improvements in adults with moderate to severe atopic dermatitis.

Medications, plants, and more may play a significant role in systemic contact dermatitis.

Andrew Blauvelt, MD, MBA, reviews recent advances in the therapeutic landscape for moderate to severe atopic dermatitis.

In their session, “Translating Evidence into Practice: Atopic Dermatitis Guidelines,” at the current AAD annual meeting, Jonathan I. Silverberg, MD, PhD, MPH, FAAD, Peter A. Lio, MD, FAAD, Andrew Blauvelt, MD, FAAD, and Robert Sidbury, MD, MPH, FAAD, discuss updates in new therapies, clinical pearls, and potential co-morbidities.